A prodrug and its active product can produce different pharmacokinetic findings in the same study. Analytical interference can complicate the comparison further. A historical 2016 lisdexamfetamine experiment shows why both analytes and the specimen’s characteristics belong in the interpretation.
What was the study design?
Forty adults, eight in each of five renal-function groups, received a single oral 30-mg dose of lisdexamfetamine dimesylate. Groups ranged from normal renal function to end-stage renal disease requiring hemodialysis. This was an open-label pharmacokinetic study, not a trial of treatment effectiveness or overdose management.
For participants not requiring dialysis, blood sampling continued for 96 hours. The dialysis group received separate predialysis and postdialysis doses with a 7–14-day washout. Investigators measured plasma lisdexamfetamine, the prodrug, and d-amphetamine, the active product, and examined dialysate recovery.
What happened to active d-amphetamine?
Overall d-amphetamine exposure increased and its half-life lengthened as renal impairment increased, while mean peak concentration decreased. Weight-adjusted apparent clearance in end-stage disease was approximately 50% lower than in normal renal function. These findings concern the tested single-dose conditions.
A lower peak and greater overall exposure are compatible because they summarize different parts of the concentration–time profile. A single plasma value cannot substitute for the serial sampling used to estimate area under the curve or elimination.
Why were prodrug results less straightforward?
Mean lisdexamfetamine peak and exposure measures in mild to severe impairment were not substantially different from normal renal function. In the dialysis group, however, unexpectedly variable lisdexamfetamine results led investigators to identify a sample-related matrix effect.
The assay had been validated using plasma from people whose renal impairment was less severe. Validation had not revealed the interference later encountered in end-stage-disease samples. The authors therefore cautioned that the apparent magnitude of higher prodrug exposure in that group could not be determined accurately.
What does that analytical limitation mean?
Validation is evidence for the matrices actually tested. A specimen can differ from ordinary plasma in ways that alter measurement, even when it has the same general specimen label. An unexpected result may require investigation of the assay as well as the patient’s physiology.
The limitation was analyte-specific in the report. It should not be silently transferred to every d-amphetamine measurement, nor ignored when interpreting lisdexamfetamine. Keeping the two analytical records separate prevents a prodrug finding from being mistaken for active-drug exposure.
Did dialysis remove substantial drug?
Little d-amphetamine was recovered: a mean of 2.63%, with a reported range of 2.18%–3.30%. Lisdexamfetamine recovery was almost absent. “Little” is more precise than claiming that exactly zero active drug was recovered.
These observations came from a small renal-impairment study after the specified dose and dialysis sessions. They do not establish outcomes in overdose, compare every dialysis technique or reconstruct an individual’s exposure history. The paper’s dosing recommendations are historical and are not reproduced here as current prescribing guidance.
What should a forensic interpretation preserve?
Preserve the dose as lisdexamfetamine dimesylate, rather than relabeling 30 mg as 30 mg of d-amphetamine. Identify the measured analyte, plasma or dialysate, sampling interval and renal group. The study illustrates distinct physiological and analytical uncertainties; it does not convert a blood concentration into functional impairment.
Source
A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function. Therapeutic Drug Monitoring. 2016;38(4):546–555. DOI: 10.1097/FTD.0000000000000296. Full text; bibliographic record.